Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Kim Tsuchimoto Sells 1,199 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Kim Tsuchimoto sold 1,199 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $70.10, for a total transaction of $84,049.90. Following the completion of the sale, the director directly owned 1,199 shares in the company, valued at $84,049.90. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $67.22 on Friday. Monopar Therapeutics Inc. has a 1 year low of $50.07 and a 1 year high of $124.82. The firm has a 50 day moving average price of $87.73 and a 200 day moving average price of $77.39.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. Equities research analysts expect that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Cantor Fitzgerald downgraded Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $109.00 to $119.00 in a report on Thursday, August 13th. BTIG Research upped their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Zacks Research downgraded Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Finally, HC Wainwright raised their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $122.00.

Monopar Therapeutics News Summary

Here are the key news stories impacting Monopar Therapeutics this week:

• Neutral Sentiment: Monopar was projected to announce quarterly earnings on Thursday. The article did not provide results or specific expectations, leaving investors to look for updates in the report. Monopar earnings announcement preview
• Neutral Sentiment: A separate article about investment firms’ views on MNPR supplied no details on ratings, price targets, or recent positioning. Investment firms’ views on MNPR
• Negative Sentiment: Directors Kim Tsuchimoto and Raymond Anderson reported share sales. Tsuchimoto sold 2,891 shares on Nov. 4 and 1,199 on Nov. 2; Anderson sold 3,142 shares on Nov. 2. The sales reduced their holdings and could weigh on sentiment, though they were executed under pre-arranged Rule 10b5-1 plans. SEC filing on director share sales

Institutional Trading of Monopar Therapeutics

Several large investors have recently added to or reduced their stakes in MNPR. Siren L.L.C. lifted its stake in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Monopar Therapeutics by 21.2% in the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company’s stock valued at $4,307,000 after buying an additional 13,761 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Monopar Therapeutics in the first quarter valued at about $3,458,000. Finally, Bank of America Corp DE raised its holdings in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after buying an additional 53,336 shares during the period. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company’s research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.

Monopar’s pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.